Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $31.0952W HIGH $106.93
Volume
1.87 M
Value Traded
200.07 M
Short % Float
10.97%
+0.15%Week
+0.45%1 Month
+17.47%3 Month
+102.6%6 Month
+1,554.95%5 Year
+691.93%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
9.19 B
EPS (TTM)
-1.02
P/E Ratio
-
Ent. Value
9.00 B
Total Shares
85.99 M
Float Shares
78.31 M
Insiders
9.90%
Institutions
76.31%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
VRNA Catalyst Timeline
Dated clinical, regulatory and corporate events for Verona Pharma plc Sponsored ADR
Past FDA Catalysts and PDUFA Decisions
How VRNA actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-12-31 | Ohtuvayre (ensifentrine) | Phase 3 data presentation | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
F15 / 100
Pipeline Score
$0M
Pipeline Value
Not rated
Valuation Signal
1
Drugs Scored
-
rNPV / MCap
Verona Pharma plc Sponsored ADR has significant pipeline risk (15/100), with 1 assets in development.
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Ensifentrine Dose 1 Small moleculeMarketedNCT04527471 | Coronavirus Infection | Phase 2 | COMPLETED | 45 | May 1, 2021 |
Clinical Trial Results
Readouts, endpoints and source filings for every VRNA program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| Ohtuvayre | COPD | Phase 3 | 2025-09-16 | statistically significant and clinically meaningful improvements in lung functionRead More | Verona Pharma to Present Additional Analyses of the Phase 3 ENHANCE Studies in COPD at ERS International Congress 2025Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Fisher AndrewOfficer (General Counsel) | Option | 931,984 931,984 held | $0.00 | 10/07/2025 |
Hedge Fund 13F Activity
Hedge Funds invested in VRNA
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 10.8 % (-15.6 %) | 361.10 M | 3.38 M |
VRNA Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How VRNA ranks across every disease it competes in
Competitive Position is a premium feature
See how VRNA ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialVRNA News
About Verona Pharma plc Sponsored ADR
Founded28-04-2017
BIOPHARMAWATCH ELITE PLUS
Trade the next VRNA catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime